OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Practicing Medicine in Wartime Ukraine	204
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	202
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	189
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	121
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	113
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	111
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	111
Localized In Vivo Prodrug Activation Using Radionuclides	109
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	103
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	100
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	98
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	94
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities	92
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	89
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	88
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	84
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	83
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	77
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	76
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	74
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	74
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	69
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	66
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma	65
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	62

Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)	61
Molecular Imaging Leadership in Academia and Industry	60
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	60
Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer	59
First-in-Human Study of [¹¹C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain	57
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection	56
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	54
Challenges with¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice	53
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?	53
Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging	52
The Role of Molecular Imaging in Precision Oncology	50
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer	49
¹⁸F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol	49
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	49
Biodistribution, Safety Profile, and Radiation Dosimetry of [¹⁸F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects	49
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	48
Funding Reductions Threaten the Future of Medical Innovation	47
Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics	47
⁶⁸Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism	46
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	46
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	45
Precision Medicine Clinical Trials	45
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors	45
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	44
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	43
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	42
High-Resolution Silicon Photomultiplier Time-of-Flight Dedicated Head PET System for Clinical Brain Studies	42
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	42
Nanoparticle Diagnostics and Theranostics in the Clinic	41
Dual-Time-Point Posttherapy¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome	41
Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies	41
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer	40
Early-Phase¹⁸F-Florbetapir and¹⁸F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting	40
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	39
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer	38
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on¹⁸F-FDG PET/MRI and Machine Learning	38
Intrapatient 16α-[¹⁸F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast	38
Perspectives on Cutting-Edge Clinical Trials	38
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem	38
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council	37
CD38-Targeted⁸⁹Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care	37
Feasibility of¹⁷⁷Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer	37
Molecular Imaging, Radiochemistry, and Environmental Pollutants	36
Tumor Dose–Response Relationship of [¹³¹I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [¹²⁴I]MIBG PET	36
An External, Independent Validation of anO-(2-[¹⁸F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma	36
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice	35
Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from ⁶⁸Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors	35
Evaluating Bone Healing with [¹⁸F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment	35
A Path to Qualification of PET/MRI Scanners for Multicenter Brain Imaging Studies: Evaluation of MRI-Based Attenuation Correction Methods Using a Patient Phantom	35
MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling	35

Green Nuclear Medicine and Radiotheranostics	35
Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma	35
Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots	34
Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA: A Multicenter Retrospective Analysis	34
Is It Too Soon to Know When It’s LATE?	34
Pretargeted Radioimmunotherapy of Ovarian Cancer with²²⁵Ac and an Internalizing Antibody	34
Bringing VISION to Nuclear Medicine: Accelerating Evidence and Changing Paradigms with Theranostics	34
First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion	33
Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study	33
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies	33
First Safety and Efficacy Data with the Radiohybrid¹⁷⁷Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer	33
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET	33
Comparison of Baseline⁶⁸Ga-FAPI and¹⁸F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibit	31
First-in-Human Evaluation of Site-Specifically Labeled⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer	31
Tau PET Imaging in Neurodegenerative Disorders	31
Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma	31
Comparison of ¹¹C-Pittsburgh Compound B and ¹⁸F-Flutemetamol White Matter Binding in PET	31
¹⁷⁶Lu Radiation in Long–Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety	31
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results	30
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy	30
Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins	30
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins	30
Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET	30
Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer	29
Posterior Cingulate Involvement Does Not Argue Against LATE	29
The Rise of Molecular Image–Guided Robotic Surgery	29
Potential of¹⁸⁸Re as an Alternative to¹⁷⁷Lu and Dosimetric Consequences	29
Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Pr	29
Identification of (R)-[¹⁸F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development	29
The Imperative for Comparative Studies in Nuclear Medicine: Elevating¹⁷⁷Lu-PSMA-617 in the Treatment Paradigm for mCRPC	29
Not All Gatekeepers Are Theranostics	28
Radionuclide Imaging of the Gut–Brain Axis in Parkinson Disease	28
Molecular Imaging in Breast Cancer	28
MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy	27
First-in-Human Study of¹⁸F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding	27
How Many Theranostics Centers Will We Need in the United States?	27
Modeling early radiation DNA damage occurring during [¹⁷⁷Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy	27
MIRD Pamphlet No. 29: MIRDy90—A⁹⁰Y Research Microsphere Dosimetry Tool	27
⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study	27
Total Body PET – Will it Change Science and Practice?	27
Quantitative Brain Amyloid PET	27
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections	27
Histologic Ex Vivo Validation of the [¹⁸F]SITATE Somatostatin Receptor PET Tracer	27
Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?	27
Tau PET Visual Reads: Research and Clinical Applications and Future Directions	27
[⁶⁸Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis	27
A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy	27
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis	27
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study	26
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer	26
Distinguishing Progression from Pseudoprogression in Glioblastoma Using¹⁸F-Fluciclovine PET	26
Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination	26
Diagnostic Potential of Supplemental Static and Dynamic⁶⁸Ga-FAPI-46 PET for Primary¹⁸F-FDG–Negative Pulmonary Lesions	26
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior²²³Ra (RALU Study)	26
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective	26
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?	26
Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease	26
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients	26
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides	26
Amino Acid PET in Neurooncology	26
Recent Evidence on Cardiac^99mTc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis	25
Delayed Imaging Improves Lesion Detectability in [^99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer	25
⁶⁴Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space	25
Association of Free-to-Total PSA Ratio and¹⁸F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Si	25
Detecting CXCR4 Expression in Meningioma on⁶⁸Ga-Pentixafor PET/MRI	25
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy	25
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent	24
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [¹⁸F]FDG PET/CT and¹³¹I Posttreatment Scanning	24
^99mTc-MIP-1404 SPECT/CT Companion Diagnostic for¹⁷⁷Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer	24
Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW	24
[¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy	24
Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists	24
FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders	24
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for¹⁶¹Tb Compared with¹⁷⁷Lu with a Higher Dose Response for [¹⁶	23
Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial	23
Stakeholders of Theranostics	23
China’s Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact	23
[⁶⁸Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria	23
Advancing Nuclear Medicine at the Multiomics Intersection	23
The Will Rogers Phenomenon and PSMA PET/CT	23

A Longitudinal PET/MRI Study of Colony-Stimulating Factor 1 Receptor–Mediated Microglia Depletion in Experimental Stroke	23
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas	23
Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	22
Utility of⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on⁶⁸Ga-PSMA-11 PET/CT	22
Theranostic Digital Twins: An Indispensable Prerequisite for Personalized Cancer Care	22
Theranostics in Perspective: White Paper	22
Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer	22
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET	22
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with¹⁶¹Tb and¹⁷⁷Lu: A Comparative Study	22
Safety, Dosimetry, and Feasibility of [⁶⁸Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer	22
Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose	21
Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept	21
Design, Preclinical Evaluation, and Clinical Translation of⁶⁸Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma	21
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	21
Total-Body ¹⁸F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations	21
⁶⁸Ga-FAPI-04 PET/CT in Non–Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression	21
Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RA	21
Future Directions in Molecular Imaging of Neurodegenerative Disorders	21
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy	21
Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy	21
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy	21
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy	21
The Annual Journal Impact Factor Saga	20
An ⁸⁹Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients	20
Detection of additional primary neoplasms on ¹⁸F-Fluciclovine PET/CT in patients with primary prostate cancer	20
Changes in Management After ¹⁸F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes	20
Antihormonal-Treatment Status Affects⁶⁸Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer	20
Tracking Innate Immune Activation in a Mouse Model of Parkinson’s Disease Using TREM1 and TSPO PET Tracers	20
Advancing Tomorrow’s Cancer Medicines	20
Reply: Dosimetry in Radiopharmaceutical Therapy	20
Effect of Acute Hypoxia Exposure on the Availability of A₁Adenosine Receptors and Perfusion in the Human Brain	20
First-in-Human Study of¹⁸F-Labeled PET Tracer for Glutamate AMPA Receptor [¹⁸F]K-40: A Derivative of [¹¹C]K-2	20
¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy	20
The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?	20
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸F-rhPSMA-7.3 PET/CT in patients with prostate cancer	20
A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer	20
Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic¹⁸F-FDG PET Kinetic Modeling	20
¹⁸F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors	19
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis	19
SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury	19
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up	19
PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy	19
Differences in Fibroinflammatory Activity Shown on⁶⁸Ga-FAPI-04 and¹⁸F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease	19
Virtual Biopsy: Just an AI Software or a Medical Procedure?	19
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)	19
ChatGPT: Can You Prepare My Patients for [¹⁸F]FDG PET/CT and Explain My Reports?	19
Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview	19
[¹¹C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study	19
Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies	19
Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model	19
Immunohistochemical FAP Expression Reflects⁶⁸Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma	19
⁶¹Cu-Labeled Radiotracers: Alternative or Choice?	19
Nuclear Cardiology Surrogate Biomarkers in Clinical Trials	19
Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer	19
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer	19
Advancing Clinical Trial Innovation in Pancreatic Cancer	18
Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor	18
[¹⁸F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lu	18
The Future of Nuclear Medicine in the United States	18
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of¹⁸F-FDG PET/CT and Conventional CT Imaging	18
2024 SNMMI Highlights Lecture: General Clinical Specialties	18
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for⁸⁹Zr-Trastuzumab	18
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	18
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard	18
Enhancing ²²³Ra Treatment Efficacy by Anti-β1 Integrin Targeting	18
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	18
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice	18
Imaging of the Aging Human Brain	18
Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia	18
Advancing Nuclear Medicine in Australia over 3 Decades	18
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE	18
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy	18
Total-Body Parametric Imaging Using Relative Patlak Plot	18
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET	18
From Scientist to Analyst to Strategist	18
Molecular Imaging of Pulmonary Fibrosis	18
Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients	17
Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study	17
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma	17
Validation of the ΔSUV_maxfor Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial	17
Is Routine Dosimetry Really Happening?	17
⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy	17
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data	17
Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis	17
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer	17
An¹⁸F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy	17
Biodistribution, Dosimetry, and Pharmacokinetics of⁶⁸Ga-CBP8: A Type I Collagen–Targeted PET Probe	17
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns	17
Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease	17
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM	17
Whole-Body PET Imaging in Humans Shows That¹¹C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs	17
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [¹⁸F]MK6240 Tau PET in Target Regions	17
Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention	17
Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET	17
⁶⁸Ga-Citrate PET of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates	16